BioNotebook: Dyax, MacroGenics, Vivaldi and Rexahn
This article was originally published in Scrip
Executive Summary
Dyax prices $60m offering; MacroGenics surges in first day of trading; Vivaldi acquires vaccine assets; and Rexahn licenses academic drug delivery platform.